Show simple item record

dc.contributor.authorAshcroft, J
dc.contributor.authorCairns, D
dc.contributor.authorWilliams, C
dc.contributor.authorHockaday, A
dc.contributor.authorCavenagh, J
dc.contributor.authorSnowden, J
dc.contributor.authorParrish, C
dc.contributor.authorYong, K
dc.contributor.authorCavet, James
dc.contributor.authorHunter, H
dc.contributor.authorBird, J
dc.contributor.authorPratt, G
dc.contributor.authorChown, S
dc.contributor.authorHeartin, E
dc.contributor.authorO'Connor, S
dc.contributor.authorBrown, J
dc.contributor.authorMorris, C
dc.contributor.authorCook, G
dc.date.accessioned2016-03-30T09:37:44Zen
dc.date.available2016-03-30T09:37:44Zen
dc.date.issued2015en
dc.identifier.citationOutcomes following salvage autologous stem cell transplant (ASCT2) vs low dose alkylating consolidation therapy following bortezomib-containing re-induction for relapsed multiple myeloma (MM) may be dependent on age and symptomatic status initiation of re-induction: results from the myeloma X (intensive) trial. 2015, 126 (23): Blooden
dc.identifier.urihttp://hdl.handle.net/10541/603984en
dc.language.isoenen
dc.titleOutcomes following salvage autologous stem cell transplant (ASCT2) vs low dose alkylating consolidation therapy following bortezomib-containing re-induction for relapsed multiple myeloma (MM) may be dependent on age and symptomatic status initiation of re-induction: results from the myeloma X (intensive) trial.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMid-Yorkshire Hospitals NHS Trust/Univeristy of Leeds, Wakefielden
dc.identifier.journalBlooden


This item appears in the following Collection(s)

Show simple item record